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The influence of genetic 
polymorphisms of CYP2C19 and ABCB1 
on ADP-induced platelet aggregation 
in clopidogrel-treated patients: 
A comparison between the index 
hospitalization for myocardial infarction 
and the 3-month follow-up visit
ABSTRACT
Background. Recent studies suggest that polymorphisms of genes involved in the clopidogrel metabo-
lism may be associated with an impaired drug bioactivation and possibly with unfavourable clinical out-
comes. The aim of this study was to assess the effect of selected genetic polymorphisms on adenosine 
diphosphate-induced platelet aggregation (ADP-PA) during the index hospitalization and after 3 months 
of clopidogrel therapy in patients presenting with myocardial infarction (MI).
Materials and methods. The study was designed as a single-center cohort trial with the 3-month follow-up. 
Genotyping for CYP2C19*2, CYP2C19*17, ABCB1 alleles and platelet reactivity assessment using the 
Multiplate Analyzer were performed in 157 patients.
Results. ADP-PA during the index hospitalization was significantly higher than at the 3-month follow-up 
visit regardless of the genotyp e [CYP2C19*1/*1 alleles (24.0 v. 15.5 U; p < 0.00001), CYP2C19*17 al-
lele (CT: 25.0 v. 15.0 U; p = 0.000 2; TT: 35.0 v. 22.0 U; p = 0.02) and ABCB1 allele (CC: 27.0 v. 15.0 U; 
p < 0.0002; CT 24.0 v. 17.0 U; p < 0.0005)]. In univariate analysis we failed to demonstrate any impact of 
the analyzed genetic variants on both in-hospital and 3-month ADP-PA, except for CYP2C19*17/*17 homo-
zygotes. Significantly higher values of ADP-PA were found in CYP2C19*17/*17 (TT homozygotes) allele 
carriers when compared with carriers of two wild alleles during the index hospitalization (CC: 20.0 U v. TT: 
35.0 U; p = 0.02), but not at the 3-month follow-up visit. Multivariate regression analysis revealed increased 
mean platelet volume (b = 7.2), elevated platelet count (b = 0.2) and the presence of heart failure at dis-
charge (b = 6.9), but not genetic polymorphisms, to be independent determinants of high ADP-PA during 
the index hospitalization. Similarly, elderly age (b = 3.3), high white blood cell count (b = 1.4), elevated 
platelet count (b = 0.4) and increased mean platelet volume (b = 0.1), but not genetic polymorphisms, 
were independently associated with the higher values of ADP-PA after 3 months of clopidogrel therapy.
Conclusions. On-clopidogrel platelet reactivity significantly decreases beyond the acute phase of MI re-
gardless of the genotype. Additionally, our study indicates that in clopidogrel-treated MI patients genetic 
polymorphisms are not the major determinants of the interindividual variability in platelet reactivity. However, 
due to a limited sample size, their minor contribution cannot be excluded.
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Introduction
Dual antiplatelet therapy composed of aspirin and 
a P2Y12 receptor inhibitor remains the mainstay of the 
treatment in patients with acute coronary syndromes 
(ACS) and those undergoing percutaneous coronary 
interventions (PCI). Clopidogrel, P2Y12 receptor in-
hibitor  most commonly used in Poland and in most 
of the countries worldwide, when added to the aspirin 
therapy, proved to maintain stent patency after PCI with 
a favourable safety profile and to protect ACS patients 
from ischemic events [1–3]. In the setting of elective 
PCI, clopidogrel is considered the indisputable standard 
of care (class of recommendation I, level of evidence 
A), while in ACS patients clopidogrel is recommended 
when new agents, ticagrelor and prasugrel, are unavail-
able or contraindicated (class of recommendation I, 
level of evidence B) [4].
Although the introduction of clopidogrel to the 
cardiovascular armamentarium is regarded as a great 
advance, therapy with this drug is flawed by several 
limitations, with a large interindividual variability in 
response to clopidogrel being the most important [5]. 
The topic of high on-clopidogrel platelet reactivity has 
been recently widely discussed in the literature [6–9]. 
It is estimated that 5–10% of patients do not respond 
to clopidogrel therapy, and approximately another 25% 
respond to the drug incompletely [10]. This substantial 
variability in the treatment response may be associated 
with polymorphisms of the genes encoding the hepa-
tic cytochrome P450, since clopidogrel is an inactive 
prodrug that requires two-step bioactivation [11, 12]. 
Additionally, recent studies not only suggest that 
polymorphisms of the genes involved in clopidogrel 
metabolism may be associated with an impaired 
drug bioactivation but also possibly with unfavour-
able clinical outcomes [13, 14]. Twenty five genetic 
variants encoding the CYP2C19 enzyme have been 
reported in the literature [15]. The normal activity of 
the CYP2C19 enzyme is determined by the presence 
of two wild alleles. Some of the allelic variants, parti-
cularly CYP2C19*2, lead to the complete loss of the 
CYP2C19 enzymatic activity, while others (e.g. CYP2 - 
C19*17) enhance clopidogrel bioactivation [16–20]. 
Another genetic cause of variable on-clopidogrel 
platelet reactivity may be the polymorphism of ABCB1, 
the gene encoding the P-glycoprotein involved in the 
clopidogrel absorption. The genetic variant 3435C>T 
is associated with an impaired function of the intestinal 
drug-efflux transporter and a reduced concentration of 
clopidogrel active metabolite [21]. The results of a ge-
netic sub-analysis of the TRITON-TIMI 38 trial suggest 
that clopidogrel-treated 3435C>T homozygotes may 
be exposed to an increased risk of recurrent ischemic 
events [22]. Causes of the high on-clopidogrel platelet 
reactivity include not only genetic factors, but may 
also be a consequence of non-compliance, drug–drug 
interactions, increased platelets turnover and many 
clinical variables like diabetes, heart failure, older age, 
obesity, chronic kidney disease, hypercholesterolemia 
and inflammation [10, 23, 24]. 
The aim of this study was to assess the effect of 
genetic polymorphisms on ADP-induced platelet aggre-
gation (ADP-PA) in patients presenting with myocardial 
infarction and after 3 months of clopidogrel therapy. 
Materials and methods
Study population and design
The present study was designed as a cohort trial 
with the 3-month follow-up. Patients admitted to the 
Department of Cardiology and Internal Medicine, 
Collegium Medicum, Nicolaus Copernicus University, 
Bydgoszcz and treated with primary PCI for acute 
myocardial infarction were screened for eligibility. All 
patients received a 600 mg clopidogrel loading dose, 
followed by a 75 mg maintenance dose once daily 
in conjunction with aspirin (a 300 mg loading dose, 
followed by a 100 mg maintenance dose once daily). 
Exclusion criteria were defined as follows: 
 — the need for prolonged use of oral anticoagulant 
therapy, heparin or fondaparinux;
 — bleeding disorders (including thrombocytope-
nia < 100 × 103/μL);
 — anemia (hemoglobin < 10.0 g/dL);
 — active inflammation;
 — heart failure class III and IV according to the New 
York Heart Association (NYHA) classification;
 — life expectancy < 1 year.
During the index hospitalization (on the 4th day 
after the admission at 10:00 a.m.) and at the 3-month 
follow-up visit, ADP-PA was assessed. Blood samples 
for genetic testing were collected on the 5th day. Geno-
typing was performed at the Institute of Molecular and 
Forensic Genetics, Collegium Medicum of the Nicolaus 
Copernicus University in Bydgoszcz, Poland. The study 
protocol was approved by the Ethical Committee of the 
Nicolaus Copernicus University. 
Platelet reactivity assessment
Blood samples were collected into hirudin-con-
taining tubes (Roche Diagnostics International Ltd, 
CH-6343 Rotkreuz, Switzerland). The 4th day of the 
index hospitalization was chosen for the blood sam-
pling because at this time the patient with myocardial 
infarction is usually mobile, usually leaves the coro-
nary care unit, and both aspirin and clopidogrel reach 
a steady state. ADP-PA was determined in the whole 
blood using the multiple electrode aggregometry (MEA) 
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on a new generation impedance aggregometer (Mul-
tiplate Analyzer, Roche Diagnostics International Ltd, 
CH-6343 Rotkreuz, Switzerland) according to the 
manufacturer’s instructions. The principle of MEA is 
based on the fact that the platelets get sticky upon 
activation, and, therefore, have a tendency to adhere 
and aggregate on the metal sensor wires in the test cell. 
One Multiplate test cell incorporates two independent 
sensor units, each consisting of two silver-coated highly 
conductive wires. When the activated platelets adhere 
onto the sensor wires, the electrical resistance between 
the wires rises, which is continuously registered and 
transformed into the arbitrary aggregation units (AU). 
The area under the aggregation curve (AUC) is an esti-
mator of the platelet aggregation expressed in arbitrary 
units (10 AU × min = 1 U) [25]. The definitions of both 
low platelet reactivity (LPR; ADP-PA < 19 U) and high 
platelet reactivity (HPR; ADP-PA > 46 U) were based 
on the consensus document of the Working Group on 
Thrombosis of the European Society of Cardiology [26].
Genotyping
Genomic DNA was extracted from blood accord-
ing to the standard procedures. CYP2C19*2 (CYP2- 
C19 681 G>A; rs4244285) was genotyped with a re-
al-time allelic discrimination assay on an ABI Prism 
Sequence Detector 7000 (Applied Biosystems) accord-
ing to the standard procedures. CYP2C19*17 (CYP2- 
C19 806 C>T, rs12248560) was genotyped with 
a commercially available validated drug metabolism 
genotyping assay (TaqMan Drug Metabolism Ge-
notyping Assay C_469857_10, Applied Biosystems, 
Foster City, CA, USA) with the ABI Prism Sequence 
Detector 7000 (Applied Biosystems) in accordance 
with the manufacturer’s instructions [12]. SNPs (Single 
Nucleotide Polymorphisms) in ABCB1 (rs1045542) were 
genotyped using commercial TaqMan SNP Genotyp-
ing Assays (assay IDs: rs1045642: C_7586657_20) on 
a ViiA 7 Real-Time PCR (Polymerase Chain Reaction) 
System (Life Technologies) following the manufacturer’s 
instructions. The proper assessment of genotypes was 
evaluated in a random sequencing of PCR products 
using a BigDye Terminator v. 3.1 sequencing kit and 
a 3130xl Genetic Analyzer (Applied Biosystems) [12]. 
The compatibility between the results of real-time allelic 
discrimination and direct sequencing was confirmed. 
Statistical analysis
The use of the Shapiro-Wilk test demonstrated that 
the investigated continuous variables were not normally 
distributed. Therefore, continuous results were reported 
throughout the manuscript as median values and inter-
quartile ranges. Categorical variables were compared 
using the c2 test with Yates’s correction if needed. The 
correlations were tested with the Spearman’s rank cor-
relation test. The impact of the numerous variables on 
a quantitative variable was assessed using the multiple 
regression model. A two-sided difference was consid-
ered significant at p < 0.05. The statistical analysis was 
carried out using the Statistica 10.0 package (Stat-Soft, 
Tulsa, OK, USA). 
Results 
A total of 157 patients were included in the study. 
The characteristics of the study population are provided 
in Table 1. The attendance rate at the 3-month follow-up 
visit was 100%.
ADP-PA during the index hospitalization was signifi-
cantly higher than at the 3-month follow-up visit regard-
less of the genotype (Tab. 2). Due to the small number 
of CYP2C19*2 681 G>A homozygotes, all carriers of 
the mutant allele were combined in one group con-
sisting of homozygotes AA (n = 1), and heterozygotes 
GA (n = 26) were compared with GG homozygotes 
(n = 130). There were no significant differences between 
ADP-PA during the index hospitalization and after three 
months of clopidogrel therapy for loss-of-function allele 
of CYP2C19*2 (GA and GA+AA genotypes) (Tab. 2). 
We did not find any significant differences between 
ADP-PA both during the acute phase of myocardial 
infarction and after 3 months in TT homozygotes 
and CT heterozygotes for the C3435T variant of the 
ABCB1 gene (Tab. 3). Moreover, we observed higher 
ADP-PA in CYP2C19*17/*17 (TT homozygotes) allele 
carriers comparing with carriers of wild allele, but only 
during the index hospitalization (Tab. 2, Fig. 1). To allow 
the impact assessment of both of these polymorphisms 
(*2 loss-of-function and *17 gain-of-function) on the 
individual variation of clopidogrel antiplatelet action, pa-
tients were classified into extensive metabolizer, normal 
metabolizer and poor metabolizer groups, according to 
the expected metabolic activity of the CYP2C19 enzyme. 
There were no significant differences between ADP-PA 
during the index hospitalization and after three months 
of clopidogrel therapy for extensive metabolizers, nor-
mal metabolizers and poor metabolizers (Tab. 3). We 
also compared the incidence of HPR and LPR based 
on the genotype. There were no significant differences 
in the distribution of patients with LPR, optimal platelet 
reactivity (OPR) and HPR (Tab. 4). 
In the absence of the significant association of the 
platelet aggregation with selected genetic polymor-
phisms CYP2C19*2 and ABCB1 as well as the higher 
value of platelet aggregation in patients with ultrafast 
metabolism of clopidogrel CYP2C19*17/*17, it was ver-
ified which of the selected variables influence ADP-PA 
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Table 1. Characteristics of the study population (n = 157). 
Continuous variables are presented as median (lower 
quartile–upper quartile), while categorical variables are 
presented as number (percent)
Variable Value (%)
Age (years) 60.0 (53.0–66.0)
Gender (male/female) 115/42 (73.2/26.8)
NSTEMI 22 (14)
STEMI 135 (86)
Prior diagnosis of CAD 35 (22.3)
Prior MI 13 (8.3)
Prior PCI 12 (7.6)
Prior CABG 4 (2.5)
LVEF (%) 45 (41.0–50.0)
Heart failure on admission with NYHA 
class II 
10 (6.4)
Heart failure at discharge with NYHA 
class II–IV
37 (23.6)
BMI [kg/m2] 27.9 (25.2–30.8)
Waist circumference [cm] 96.5 (90.0–103.5) 
Hyperlipidemia 98 (62.4)
Hypertension 86 (54.8)
Diabetes mellitus 54 (34.4)
Current smoker 81 (51.6)
Glycemia on admission [mg/dL] 138.0 (117.0–164.0)
WBC [103/μL] 7.58 (6.34–9.17)
RBC [106/μL] 4.52 (4.2–4.84)
HGB [g/dL] 13.5 (12.8–14.4)
HCT (%) 39.4 (37.0–42.2)
PLT [103/μL] 208.0 (176.0–241.0)
MPV [fL] 10.9 (10.3–11.4)
BNP [pg/dL] 105.2 (60.0–209.1)
hsCRP [mg/L] 9.43 (4.53–29.3)
BMI — body mass index; BNP — B-type natriuretic peptide; CABG  
— coronary artery bypass grafting; CAD — coronary artery disease;  
HCT — hematocrit; HGB — hemoglobin; hsCRP — high sensitivity  
C-reactive protein; LVEF — left ventricular ejection fraction; NYHA 
— New York Heart Association; MI — myocardial infarction; MPV — 
mean platelet volume; NSTEMI — non ST-segment elevation myocar-
dial infarction; PCI — percutaneous coronary intervention;  
PLT — platelets; RBC — red blood cells; STEMI — ST-segment eleva-
tion myocardial infarction; WBC — white blood cells
during hospitalization and after three months of clopi-
dogrel therapy. 
As indicated with univariate analysis, the mean 
corpuscular volume of erythrocytes, mean platelet 
volume, white blood cell count, platelet count, diabe-
tes, heart failure at discharge and presence of CYP2- 
C19*17/*17 influenced platelet reactivity during the hos-
pitalization (Tab. 5, 6). The Spearman’s rank correlation 
test showed significant linear correlations between the 
value of ADP-PA measured after three months for the fol-
lowing variables: age, platelet count and white blood cell 
count (Tab. 5). Univariate analysis after three months 
showed the influence of heart failure at discharge on 
the platelet aggregation (Tab. 6).
To further investigate the relationship between ADP-PA 
and both, quantitative and qualitative, variables during the 
hospitalization and after three months of clopidogrel ther-
apy, we applied multivariate regression analysis (Tab. 7). 
Mean platelet volume, platelet count and heart failure at 
discharge class II–IV NYHA were independently associ-
ated with an increase in ADP-PA during the hospitaliza-
tion. Age, white blood cells count, platelets count and 
mean platelet volume were independently associated 
with ADP-PA after three months of clopidogrel therapy 
(Tab. 7). The coefficient of multiple determination R2 was 
0.278. This model explains 27.8% of the variability of ADP-
PA during the hospitalization. The statistical significance 
of the model is p < 0.000001. After three months, the 
coefficient of multiple determination R2 was 0.223, so this 
model explains 22.3% of the variability of ADP-PA after 
three months. The statistical significance of the model 
is p < 0.000001 (Tab. 7).
Discussion
The main finding of our study is that on-clopidogrel 
platelet reactivity significantly decreases beyond the 
acute phase of myocardial infarction regardless of 
the genotype. Additionally, our study indicates that 
in clopidogrel-treated myocardial infarction patients 
genetic polymorphisms are not major determinants of 
the interindividual variability in platelet reactivity.
We found significant reduction of ADP-PA after three 
months of clopidogrel therapy, independently of the 
presence of any genetic polymorphisms. 
In a study by Campo et al., both on-clopidogrel 
platelet reactivity with the VerifyNow P2Y12 test 
and genetic polymorphisms: CYP2C19*2, *17, 
CYP3A5*3, and ABCB1 were evaluated in 300 pa-
tients before PCI intervention, one and six months 
thereafter. On-clopidogrel platelet reactivity showed 
a significant reduction from the index hospitalization 
to one month. The percentage of poor respond-
ers decreased from 35% (95% CI: 30% to 41%) at 
baseline to 13% (95% CI: 9% to 18%) at one month. 
A significant decrease of on-clopidogrel platelet 
reactivity was observed from baseline (index hospi-
talization) to one month, without further changes up 
to six months. This trend was more pronounced in 
patients admitted for non ST-segment elevation acute 
coronary syndrome, a consistent platelet reactivity 
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Table 2. Results of ADP-PA during hospitalization and after three months of clopidogrel therapy for CYP2C19*2 681 G>A, 
CYP2C19*17 806 C>T and ABCB1 3435 C>T genotypes, median (lower quartile–upper quartile)
CYP2C19*2 681 G>A GG
n = 130
GA
n = 26
GA + AA*
n = 27
p value for the 
comparison of 
ADP-PA between 
genotypes
ADP-PA — 10:00 a.m. hospitalization [U] 24.0 
(16.0–36.0)
30.0 
(16.0–36.0)
30.0 
(15.0–36.0)
0.766
ADP-PA — 3 months [U] 15.5 
(10.0–24.0)
18.5 
(14.0–27.0)
18.0 
(13.0–27.0)
0.663
p value for the comparison of ADP-PA between 
index hospitalization and after 3 months of 
clopidogrel therapy
0.00000044 0.095 0.080
CYP2C19*17 806 C>T CC 
n = 85
CT 
n = 59
TT
n = 13
p value for the 
comparison of 
ADP-PA between 
genotypes
ADP-PA – 10:00 a.m. hospitalization [U] 20.0 
(14.0–35.0)
25.0 
(16.0–33.0)
35.0
(24.0–44.0)
0.026
ADP-PA – 3 months [U] 17.0 
(11.0–26.0)
15.0 
(10.0–21.0)
22.0
(16.0–30.0)
0.115
p value for the comparison of ADP-PA between 
index hospitalization and after 3 months of 
clopidogrel therapy
0.003 0.0002 0.02
ABCB1 3435C>T CC
n = 37
CT 
n = 79
TT
n = 41
p value for the 
comparison of 
ADP-PA between 
genotypes
ADP-PA — 10:00 a.m. hospitalization [U] 27.0 
(15.0–40.0)
24.0
(17.0–37.0)
20.0
(13.0–28.0)
0.114
ADP-PA — 3 months [U] 15.0 
(8.0–23.0)
17.0
(11.0–26.0)
17.0
(12.0–25.0)
0.327
p value for the comparison of ADP-PA between 
index hospitalization and after 3 months of 
clopidogrel therapy
0.000131 0.000343 0.098
*Only one patient with genotype AA was identified — no statistical analysis was performed. ADP-PA — adenosine diphosphate induced platelet 
aggregation
Figure 1. Comparison of ADP-PA during hospitalization in relation to the presence of CYP2C19*17 806 C>T genotypes 
(marker — median, the edges of the box — the upper and lower quartile)
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Table 3. Results of ADP-PA during hospitalization and after 3 months of clopidogrel therapy, depending on the 
metabolic phenotype of clopidogrel, median (lower quartile–upper quartile)
Phenotype Extensive metabolizers
(681 GG + 806 CT or TT)
Normal metabolizers
(681 GG + 806 CC and 
681 GA or AA + 806 CT 
or TT)
Poor metabolizers
(681 GA or AA + 806 CC)
p value
n = 61 n = 80 n = 16
ADP-PA — 10:00 a.m. 
hospitalization [U]
27.0
(18.0–40.0)
20.5
(14.0–32.5)
31.5
(12.5–39.0)
0.2320
ADP-PA — 3 months [U] 16.0 
(10.0–23.0)
16.0
(11.0–25.0)
22.5
(14.5–28.0)
0.3727
ADP-PA — adenosine diphosphate induced platelet aggregation
Table 4. Comparison of distribution of low, optimal and high platelet reactivity during hospitalization between 
genotypes [n (%)]
CYP2C19*2 LPR < 19 U (n = 54) OPR 19–46 U (n = 84) HPR > 46 U (n = 19) 
GG 45 (83.33) 68 (80.95)  17 (89.47)
GA + AA 9 (16.67) 16 (19.05)  2 (10.53)
p value 0.66817
CYP2C19*17 LPR < 19 U (n = 54) OPR 19–46 U (n = 84) HPR > 46 U (n = 19)
CC 35 (64.81) 41 (48.81) 9 (47.37)
CT 19 (35.19) 33 (39.29) 7 (36.84)
TT 0 (0.00) 10 (11.90) 3 (15.79)
p value 0.06144
ABCB1 LPR < 19 U (n = 54) OPR 19–46 U (n = 84) HPR > 46 U (n = 19)
CC 11 (20.37) 20 (23.81) 6 (31.58)
CT 26 (48.15) 43 (51.19) 10 (52.63)
TT 17 (31.48) 21 (25.00) 3 (15.79)
p value 0.69018
HPR — high platelet reactivity; LPR — low platelet reactivity; OPR — optimal platelet reactivity
Table 5. Correlations between ADP-PA and quantitative variables during the index hospitalization and at 3-month 
follow-up visit
Index hospitalization 3-month follow-up
Quantitative 
variable
R Spearman’s 
rank correlation 
coefficient
p value Quantitative 
variable
R Spearman’s 
rank correlation 
coefficient
p value
MCV 0.169 0.03392 PLT 0.229 0.004098
MPV 0.203 0.01090 Age 0.285 0.000304
WBC 0.234 0.00320 WBC 0.377 < 0.000011
PLT 0.265 0.00079
MCV — mean corpuscular volume; MPV — mean platelet volume; PLT — platelet; WBC — white blood cell
modification over time was noted also in stable pa-
tients. Gene polymorphisms justified about 18% of this 
trend. CYP2C19*2 and *17 influence was apparently 
consistent over time, whereas ABCB1 showed a high-
er impact at baseline [27]. 
Our study indicates that in the clopidogrel-treated 
patients genetic polymorphisms are not major de-
terminants of the interindividual variability in platelet 
reactivity. However, in multivariate regression analysis 
mean platelet volume, platelet count and heart failure 
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Table 6. ADP-PA values with regard to analyzed factors during hospitalization and after three months of clopidogrel 
therapy
Qualitative variables ADP-PA — 10:00 a.m.  
hospitalization [U]
p value
Diabetes (+) n = 54 29.0 (18.0–40.0)
0.043
Diabetes (–) n = 103 22.0 (14.0–33.0)
Heart failure at discharge class II–IV NYHA hospitalization (+) n = 37 30.0 (18.0–43.0)
0.045
Heart failure at discharge class II–IV NYHA hospitalization (–) n = 120 22.5 (14.5–33.5)
CYP2C19*17/*17 carriers (TT homozygotes) n = 13 35.0 (24.0–44.0)
0.010
CYP2C19*17/*17 noncarriers n = 144 23.0 (14.5–34.5)
Qualitative variables ADP-PA — after 3 months of 
clopidogrel therapy [U]
p value
Heart failure at discharge class II-IV NYHA hospitalization (+) n = 37 20.0 (14.0–31.0)
0.0087
Heart failure at discharge class II-IV NYHA hospitalization (–) n = 120 15.0 (10.0–23.5)
ADP-PA — adenosine diphosphate induced platelet aggregation; NYHA — New York Heart Association
Table 7. Impact of clinical and biochemical variables on ADP-PA during index hospitalization and at 3-month follow-up visit
Model characteristics: R2 = 0.278; p < 0.000001
Variables during hospitalization Beta coefficient ± standard error p value
MPV 7.2271 ± 1.42020 < 0.00001
Heart failure at discharge class II–IV NYHA hospitalization 6.9414 ± 2.80661  0.014
PLT 0.1928 ± 0.02976 < 0.00001
Model characteristics: R2 = 0.223; p < 0.000001
Variables after 3 months of clopidogrel therapy Beta coefficient ± standard error p value
MPV 3.3490 ± 1.31716 0.012
WBC 1.4490 ± 0.61572 0.020
Age 0.3562 ± 0.1084 0.0013
PLT 0.1013 ± 0.025 0.00008
MCV — mean corpuscular volume; MPV — mean platelet volume; NYHA — New York Heart Association; PLT — platelets; WBC — white blood cells
at discharge are independent factors associated with 
ADP-PA during the hospitalization, while mean platelet 
volume, platelet count, white blood cell count and 
age are associated with ADP-PA after three months of 
clopidogrel therapy.
There are many variables conditioning the on-clopi-
dogrel platelet reactivity. Undoubtedly, genetic 
determinants can exert influence on the clopidogrel 
metabolism. The polymorphisms of genes encoding 
the hepatic cytochrome enzymes and P-glycoprotein 
are acknowledged major factors of the interindividual 
clopidogrel response. There are many combinations 
of different CYP2C19 alleles impairing or enhancing 
activity of this enzyme [28]. It is of high importance, 
especially in patients after ACS, because a decreased 
response to antiplatelet therapy in this group may lead 
to atherothrombotic complications including myocar-
dial infarction, stent thrombosis, distal thromboem-
bolism or stroke [8]. The prevalence of alleles differs 
widely between populations. It has been shown that 
as many as about 25% of the Polish population are 
CYP2C19*2 heterozygotes, while about 2% are CYP2 - 
C19 2/*2 homozygotes [29]. The CYP2C19*17 allele 
is pretty common and accounts for 43% of the Polish 
population [29]. This data is consistent with our ob-
servations (Tab. 8).
The presence of CYP2C19*2 allele in healthy volun-
teers was associated with a significantly lower inhibition of 
platelet reactivity comparing to carriers of wild allele [19]. 
In the study by Collet et al., they found a strong correla-
tion between the presence of CYP2C19*2 and recurrent 
coronary events in patients after myocardial infarction 
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on clopidogrel therapy [30]. The primary endpoint 
composed of death, myocardial infarction and urgent 
revascularization occurred significantly more often in 
carriers of mutant allele (HR [hazard ratio] 3.69; 95% CI 
[confidence interval] 1.69–8.05; p = 0.0005), moreover, 
the frequency of stent thrombosis was also higher in 
this group (HR 6.02; 95% CI 1.81–20.04; p = 0.0009). 
Multivariable analysis showed the presence of CYP2- 
C19*2 to be a single independent predictor of car-
diovascular events (HR 4.04; 95% CI 1.81–9.02; 
p = 0.0006). Similarly, Sibbing and co-workers found 
a threefold higher occurrence of stent thrombosis in the 
presence of CYP2C19*2 mutation as compared with 
the wild type homozygous patients (p = 0.007) [31]. 
The researchers of the genetic substudy of TRITON-TIMI 
38 trial (Trial to assess improvement in therapeutic out-
comes by optimizing platelet inhibition with prasugrel 
TIMI 38) collected genetic data of almost 1500 patients 
with ACS treated with either prasugrel or clopidogrel [32]. 
Over 27% of them were the carriers of mutant allele 
and presented with the significantly lower concen-
trations of clopidogrel active metabolite comparing 
with non-carriers, they were at the increased risk of 
the primary end-point composed of death from car-
diovascular causes, myocardial infarction and stroke 
(HR 1.53; 95% CI 1.07–2.19; p = 0.01). On the other 
hand, the results of the CHARISMA (Clopidogrel for 
high atherothrombotic risk and ischemic stabilization, 
management and avoidance) genetics study performed 
in a group of 4819 patients with stable coronary artery 
disease revealed that the presence of CYP2C19*2 al-
lele as well as CYP2C19*17 allele did not influence 
the rate of ischemic events [33]. Similar observations 
were made by Zabalza et al. In their meta-analysis, 
they showed that carriers of loss of function allele did 
not have an increased risk of cardiovascular compli-
cations, except for stent thrombosis, while carriers of 
gain of function allele had a lower risk of cardiovascular 
events, but a higher risk of bleeding complications [34]. 
In a pharmacodynamic study, Frere et al. found that 
the CYP2C19*17 carriers exhibit the lowest level of 
phosphorylation of the intracellular vasodilator stimu-
lated phosphoprotein in flow cytometry analysis, which 
means that the platelet inhibition after a 600 mg loading 
dose of clopidogrel was the greatest in this subset of 
patients [18]. Also in a study by Sibbing and colleagues 
they assessed ADP-PA in CYP2C19*17 carriers, and 
found a significantly reduced platelet reactivity, which 
was associated with an increased bleeding risk in this 
group comparing to wild-type homozygotes [35].
The polymorphism of gene ABCB1 encoding P-glyco- 
protein, which regulates the transmembrane trans-
port of clopidogrel, may result in an increased risk 
of cardiovascular events. Simon et al. found that car-
riers of two variant alleles 3435 C>T had a higher rate 
of atherothrombotic complications including myocardi-
al infarction, death from any cause and non-fatal stroke, 
comparing to carriers of wild allele in the population 
of patients with myocardial infarction [14]. In the above 
mentioned genetic substudy of TRITON-TIMI, 38 trial 
carriers of two variant alleles 3435 C>T treated with 
clopidogrel had a higher platelet reactivity and were 
at increased risk of recurrent ischemic events [22]. 
Our observations did not confirm that the presence 
of CYP2C19*2 allele or ABCB13435 C>T was asso-
ciated with a significantly lower inhibition of platelet 
reactivity comparing to carriers of wild allele, and the 
results did not confirm the increased ADP-PA in pa-
tients presenting with polymorphisms of CYP2C19*17. 
However, some reports could not confirm the impact 
of CYP2C19*2 on clinical outcome [12, 33]. This 
discrepancy might be explained by the fact that the 
CYP2C19*2 allele accounts only for 5–12 % of the 
variation in the response to clopidogrel [36, 37]. 
Thus, available data suggest that other variables like 
unknown genetic variants or other not identified factors 
contribute to this phenomenon.
Generally, according to a study by Hoshino et al., 
the level of platelet inhibition during clopidogrel therapy 
is constant in stable conditions [38]. It has been shown 
that mean platelet volume (MPV), is a marker of platelet 
reactivity [39]. An increased MPV is associated with 
myocardial damage in ACS and with unfavorable out-
come among survivors of myocardial infarction [40, 41]. 
Chu et al. observed a decrease in MPV in subjects with 
ACS [42]. Nevertheless, higher platelet reactivity in the 
acute phase of myocardial infarction may be associated 
with enhanced platelet turnover [43]. Another import-
Table 8. Genotype distribution in the study population 
[number (percent)]
Genotypes n = 157
CYP2C19*2 681 G>A n (%)
GG 130 (82.8)
GA 26 (16.6)
AA 1 (0.6)
CYP2C19*17 806 C>T n (%)
CC 85 (54.1)
CT 59 (37.6)
TT 13 (8.3)
ABCB1 3435C>T n (%)
CC 37 (23.6)
CT 79 (50.3)
TT 41 (26.1)
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ant factor influencing platelet aggregation is platelet 
count. Wu et al., in a meta-analysis comprising a total 
of 39,324 patients with ACS, demonstrated that a higher 
platelet count enhances the risk of mortality and major 
cardiac adverse events [44].
Furthermore, activated platelets take part in me-
diation of the inflammatory response interacting with 
leukocytes and producing cytokines in the acute phase 
of ACS [45]. Inflammation, as assessed by the white 
blood cell count, is a well-documented risk factor of 
a decreased platelet response to clopidogrel [46, 47]. 
In a study by Osmancik et al. they found higher white 
blood cell count and interleukin-10 concentration as de-
terminants for non-responsiveness to clopidogrel [48]. 
Cuisset et al. found significantly higher platelet 
reactivity in response to clopidogrel in older patients 
(> 75 years of age) with non-ST-elevation ACS [49]. 
According to multivariate analysis performed after three 
months of clopidogrel therapy, in our population age 
is also an important factor affecting the on-treatment 
platelet function. 
Our findings suggest that heart failure at discharge 
(NYHA II–IV) is a clinical factor influencing the antiplate-
let effect of clopidogrel, according to the multivariate 
analysis in the index hospitalization. Patients with heart 
failure may be predisposed to a hypercoagulable or 
prothrombotic state [50, 51]. In patients with heart 
failure activation of the sympathetic nervous system is 
associated with activation of the platelet function [52].
Limitations of the study
Several limitations of our study should be ac-
knowledged. Firstly, we applied only one method of 
the platelet function assessment. Secondly, due to 
a limited sample size, we were not able to evaluate 
the impact of the investigated polymorphisms on clin-
ical outcomes. Thirdly, we cannot exclude the minor 
contribution of the analyzed genetic variants to the 
interindividual variability of on-clopidogrel platelet reac-
tivity. Fourthly, participants’ adherence to clopidogrel 
therapy during the 3-month follow-up was not objec-
tively proved. However, all patients declared systematic 
intake of clopidogrel. Finally, we cannot exclude the 
influence of other variables, which were not included 
in the analysis, on ADP-PA.
Conclusions
On-clopidogrel platelet reactivity significantly de-
creases beyond the acute phase of myocardial infarc-
tion regardless of the genotype. Additionally, our study 
indicates that in the clopidogrel-treated myocardial 
infarction patients genetic polymorphisms are not major 
determinants of the interindividual variability in platelet 
reactivity. However, due to a limited sample size, their 
minor contribution cannot be excluded.
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